Vancouver, British Columbia – TheNewswire – May 26, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP)(OTC:NSPDF) is pleased to provide the following update regarding progress for a Phase 2 clinical trial treatment for COVID 19. The Company is pleased to announce that a Clinical Trial Application (CTA) has been submitted to Health Canada for a COVID-19 Phase 2 clinical trial, using Cavaltinib(TM) as the subject test drug . The same study protocol is being prepared for submission to the U.S. FDA regulatory authorities.